-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ivermectin is an antiparasitic drug that is included in the World Health Organization (WHO) standard list of essential drugs and is widely used worldwide.
In 2015, the two scholars who jointly discovered the drug and Chinese scientist Tu Youyou shared the Nobel Prize in Physiology or Medicine that year.
In vivo or in vitro experiments, it has the effect of killing various pathogens.
With its many years of human medicine basis and strong pharmacological effects, many scientists believe that this medicine may form the basis of a new coronavirus vaccine.
On April 3, 2020, Antiviral Research published online the major findings of the Monash University research team in Australia.
Experimental test results showed that Ivermectin can treat new coronary pneumonia.
The drug can eliminate any traces of the virus within two days.
The team Said that it is expected to enter human trials within one month at the earliest.
However, this research on ivermectin was only carried out on cells cultured in the laboratory and is still in its infancy.
There is currently no evidence to verify its efficacy on humans.
Recently, a joint research team from Colombia published a research paper entitled "Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19" in the journal of the American Medical Association.
For the first time, this study demonstrated through a randomized controlled experiment that ivermectin is not suitable for the treatment of mild COVID-19.
In this study, the researchers surveyed a number of local patients with mild new coronary pneumonia from July 15 to December 21, 2020.
The patients were randomly assigned to take oral ivermectin or ivermectin at a ratio of 1:1.
Placebo.Experimental flowchart The research team used the 8-category number table that is often used in COVID-19 treatment experiments to score patients.
The test results are mainly classified according to two types of factors.
The main factors are from randomization to complete relief of symptoms.
Time, the secondary factor is patients who have worsened by 2 points (starting from the baseline score of the 8-category ordinal scale) since random assignment.
Among the 476 patients who received randomization, 238 were assigned to receive ivermectin treatment, and 238 received placebo treatment.
There was no significant difference in the time to symptom relief between the ivermectin group and the placebo group (median : 10 days vs 12 days; the difference is -2 days [IQR, -4 to 2]); few patients have a clinical deterioration score of more than 2 points, and there is no significant difference between the 2 treatment groups (ivermectin 2% in the group and 3.
5% in the placebo group; the absolute difference was -1.
53 [95% CI, -4.
75 to 1.
69]).
Preliminary analysis of the time for symptom relief in the population.
By analyzing the patient data, the research team found that in adults with mild COVID-19, compared with placebo, the 5-day course of ivermectin did not significantly improve Time to symptom relief.
This finding does not support the use of ivermectin to treat mild COVID-19, although larger trials may be needed to understand the effect of ivermectin on other clinically relevant outcomes.
All in all, although ivermectin is not suitable for the treatment of mild COVID, as a well-known star drug, ivermectin has made great achievements in the struggle against parasitic diseases and saved the number of people.
Millions of lives.
With the rapid development of medical technology, the parasitic diseases, bacterial infections, and viral infectious diseases that once ravaged human society have been initially controlled.
At present, chronic diseases such as cancer, cardiovascular and cerebrovascular diseases, and diabetes have become the primary factors threatening human health.
However, these once-famous drugs can still give people new inspiration in the "old drugs and new applications"! Original source: Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19A Randomized Clinical TrialJAMA.
Published online March 4, 2021.
doi:10.
1001/jama.
2021.
3071 For more information, please click to read the original download Metz Medical App~
In 2015, the two scholars who jointly discovered the drug and Chinese scientist Tu Youyou shared the Nobel Prize in Physiology or Medicine that year.
In vivo or in vitro experiments, it has the effect of killing various pathogens.
With its many years of human medicine basis and strong pharmacological effects, many scientists believe that this medicine may form the basis of a new coronavirus vaccine.
On April 3, 2020, Antiviral Research published online the major findings of the Monash University research team in Australia.
Experimental test results showed that Ivermectin can treat new coronary pneumonia.
The drug can eliminate any traces of the virus within two days.
The team Said that it is expected to enter human trials within one month at the earliest.
However, this research on ivermectin was only carried out on cells cultured in the laboratory and is still in its infancy.
There is currently no evidence to verify its efficacy on humans.
Recently, a joint research team from Colombia published a research paper entitled "Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19" in the journal of the American Medical Association.
For the first time, this study demonstrated through a randomized controlled experiment that ivermectin is not suitable for the treatment of mild COVID-19.
In this study, the researchers surveyed a number of local patients with mild new coronary pneumonia from July 15 to December 21, 2020.
The patients were randomly assigned to take oral ivermectin or ivermectin at a ratio of 1:1.
Placebo.Experimental flowchart The research team used the 8-category number table that is often used in COVID-19 treatment experiments to score patients.
The test results are mainly classified according to two types of factors.
The main factors are from randomization to complete relief of symptoms.
Time, the secondary factor is patients who have worsened by 2 points (starting from the baseline score of the 8-category ordinal scale) since random assignment.
Among the 476 patients who received randomization, 238 were assigned to receive ivermectin treatment, and 238 received placebo treatment.
There was no significant difference in the time to symptom relief between the ivermectin group and the placebo group (median : 10 days vs 12 days; the difference is -2 days [IQR, -4 to 2]); few patients have a clinical deterioration score of more than 2 points, and there is no significant difference between the 2 treatment groups (ivermectin 2% in the group and 3.
5% in the placebo group; the absolute difference was -1.
53 [95% CI, -4.
75 to 1.
69]).
Preliminary analysis of the time for symptom relief in the population.
By analyzing the patient data, the research team found that in adults with mild COVID-19, compared with placebo, the 5-day course of ivermectin did not significantly improve Time to symptom relief.
This finding does not support the use of ivermectin to treat mild COVID-19, although larger trials may be needed to understand the effect of ivermectin on other clinically relevant outcomes.
All in all, although ivermectin is not suitable for the treatment of mild COVID, as a well-known star drug, ivermectin has made great achievements in the struggle against parasitic diseases and saved the number of people.
Millions of lives.
With the rapid development of medical technology, the parasitic diseases, bacterial infections, and viral infectious diseases that once ravaged human society have been initially controlled.
At present, chronic diseases such as cancer, cardiovascular and cerebrovascular diseases, and diabetes have become the primary factors threatening human health.
However, these once-famous drugs can still give people new inspiration in the "old drugs and new applications"! Original source: Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19A Randomized Clinical TrialJAMA.
Published online March 4, 2021.
doi:10.
1001/jama.
2021.
3071 For more information, please click to read the original download Metz Medical App~
